A solid Eylea franchise and Dupixent's potential support Regeneron's narrow moat.
We’re lowering our Regeneron fair value estimate to $405 per share from $500 following third-quarter results, as we’ve factored in a slower launch for atopic dermatitis drug Dupixent and arthritis drug Kevzara, weaker sales of Praluent following lost market share to Amgen’s Repatha, concerns surrounding long-term Dupixent competition in atopic dermatitis and asthma, and slight declines in our long-term Eylea forecast (assuming biosimilars in 2024). These changes were partly countered by lower-th...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.